Dashboard
Manage Tickers

JSPRJasper Therapeutics, Inc.

Nasdaq www.jaspertherapeutics.com


$ 20.88 $ 0.16 (0.77 %)    

Tuesday, 14-May-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 445.88 $ 2.85 (0.64 %)
DIA $ 395.58 $ 1.12 (0.28 %)
SPY $ 523.16 $ 2.39 (0.46 %)
TLT $ 90.86 $ 0.51 (0.56 %)
GLD $ 218.12 $ 1.83 (0.85 %)
$ 20.92
$ 21.30
$ 0.00 x 0
$ 0.00 x 0
$ 20.84 - $ 21.38
$ 4.00 - $ 31.01
39,211
na
315.59M
$ 1.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-05-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-18-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-24-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-26-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jasper-therapeutics-q1-eps-103-beats-123-estimate
Jasper Therapeutics Q1 EPS $(1.03) Beats $...
05/14/2024 12:35:05

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $...

jasper-therapeutics-plans-to-initiate-phase-1b2a-study-of-briquilimab-in-patients-with-asthma-in-q4
Jasper Therapeutics Plans To Initiate Phas...
05/13/2024 12:02:41

spirit-airlines-posts-weak-results-joins-integra-lifesciences-bowlero-and-other-big-stocks-moving-lower-on-monday
Spirit Airlines Posts Weak Results, Joins ...
05/06/2024 17:05:12

hc-wainwright--co-initiates-coverage-on-jasper-therapeutics-with-buy-rating-announces-price-target-of-65
HC Wainwright & Co. Initiates Coverage On ...
05/06/2024 10:40:25

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and a...

evercore-isi-group-initiates-coverage-on-jasper-therapeutics-with-outperform-rating-announces-price-target-of-65
Evercore ISI Group Initiates Coverage On J...
04/03/2024 11:34:01

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rat...

rbc-capital-initiates-coverage-on-jasper-therapeutics-with-outperform-rating-announces-price-target-of-70
RBC Capital Initiates Coverage On Jasper T...
03/28/2024 08:36:23

RBC Capital analyst Gregory Renza initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating and annou...

jasper-therapeutics-announces-first-patient-dosed-in-phase-1b2a-spotlight-clinical-study-of-briquilimab-in-chronic-inducible-urticaria
Jasper Therapeutics Announces First Patien...
03/19/2024 12:05:22

Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibo...

td-cowen-initiates-coverage-on-jasper-therapeutics-with-outperform-rating
TD Cowen Initiates Coverage On Jasper Ther...
03/18/2024 12:34:14

TD Cowen analyst Yaron Werber initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating.

jasper-therapeutics-announces-new-data-presented-on-briquilimab-conditioning-in-patients-with-fanconi-anemia
Jasper Therapeutics Announces New Data Pre...
03/15/2024 12:04:44

Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanco...

oppenheimer-maintains-outperform-on-jasper-therapeutics-maintains-80-price-target
Oppenheimer Maintains Outperform on Jasper...
03/07/2024 13:02:28

Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $80 price target.

jasper-therapeutics-won-clearance-for-initiation-of-its-phase-1b2a-beacon-study-of-subcutaneous-briquilimab-in-csu-phase-1b2a-spotlight-study-initiated-a-phase-1-trial-of-briquilimab-as-second-line-therapy-in-subjects-with-myelodysplastic-syndromes
Jasper Therapeutics Won Clearance for Init...
03/04/2024 12:39:22

Highlights for 2023 and Recent Weeks Successfully completed an underwritten offering of 3,900,000 shares of its common stock...

jasper-therapeutics-reported-fy23-eps-loss-of-150-cash-balance-of-869m
Jasper Therapeutics Reported FY23 EPS Loss...
03/04/2024 12:35:36

Fiscal 2023 Financial Results Cash and cash equivalents as of December 31, 2023, totaled $86.9 million.   Research and...

jasper-therapeutics-presents-data-from-preclinical-briquilimab-studies-at-the-american-academy-of-allergy-asthma-and-immunology-annual-meeting
Jasper Therapeutics Presents Data From Pre...
02/23/2024 13:06:42

 Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antib...

over-15m-bet-on-aon-check-out-these-3-stocks-insiders-are-buying
Over $15M Bet On Aon? Check Out These 3 St...
02/12/2024 13:36:25

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

why-fmc-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why FMC Shares Are Trading Lower By Around...
02/06/2024 18:17:47

Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fo...

jasper-therapeutics-announces-pricing-of-50m-underwritten-offering-of-39m-shares-of-common-stock-at-a-price-of-1295share
Jasper Therapeutics Announces Pricing Of $...
02/06/2024 14:01:07

Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical-stage biotechnology company focused on developing novel ...

jasper-therapeutics-announces-preclinical-data-presentations-at-american-academy-of-allergy-asthma-and-immunology-annual-meeting
Jasper Therapeutics Announces Preclinical ...
02/05/2024 13:11:15

etails of the presentations are as follows:Abstract Title: Briquilimab, An Anti-CD117 Antibody, Prevents Passive Systemic Anaph...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
01/18/2024 17:31:14

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
01/17/2024 17:31:12

jasper-therapeutics-announces-recent-accomplishments-and-upcoming-milestones
Jasper Therapeutics Announces Recent Accom...
01/05/2024 13:36:55

- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Pa...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION